7 recruiting, 3 active not recruiting. 3 Phase 1, 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 3 | 3 | Active not recruiting 2, Recruiting 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow HER2 Negative Breast Carcinoma: new trials by email Literature Review of HER2 Negative Breast Carcinoma trials Research Report on HER2 Negative Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer Neoadjuvant endocrine therapy - Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 176 | 2026-03-13 | 2026-06-04 |
| Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer Palazestrant, Letrozole-matching placebo, Ribociclib - Breast Cancer, Locally Advanced Breast Cancer | Phase 3 | Recruiting | Olema Pharmaceuticals, Inc. | 1000 | 2025-11-03 | 2026-09-23 |
| Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer Specimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Medical Record Review - HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma | Recruiting | University of California, San Francisco | 100 | 2025-10-08 | 2026-10-16 | |
| A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer Abemaciclib, Radiation Therapy - Metastatic Breast Cancer, Stage IV Breast Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 28 | 2024-11-15 | 2026-05-28 |
| DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients Biospecimen Collection - HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer | Recruiting | Mayo Clinic | 100 | 2024-04-30 | 2026-06-01 | |
| DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs Datopotamab Deruxtecan - Breast Cancer, Breast Cancer Female | Phase 2 | Recruiting | Nancy Lin, MD | 58 | 2024-01-08 | 2026-08-06 |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer Palazestrant, Fulvestrant, Anastrozole - Breast Cancer, Advanced Breast Cancer | Phase 3 | Active not recruiting | Olema Pharmaceuticals, Inc. | 510 | 2023-11-16 | 2026-08-13 |
| Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy Educational Intervention, Text Message-based Navigation Intervention, Motivational Interviewing - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 1167 | 2021-02-15 | 2026-10-19 |
| SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells Melphalan, BCNU, Vitamin B12B - Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation | Phase 1 | Recruiting | General Oncology, Inc. | 24 | 2021-01-13 | 2026-01-29 |
| Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Laboratory Biomarker Analysis - HER2 Negative Breast Carcinoma, Recurrent Breast Carcinoma | Phase 1 | Active not recruiting | University of Washington | 42 | 2015-06-01 | 2026-02-17 |
Breast Neoplasms (9) · Triple Negative Breast Neoplasms (2) · Carcinoma, Lobular (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Recurrence (1)
Breast Diseases (9) · Neoplasms (9) · Neoplasms by Site (9) · Skin Diseases (9) · Skin and Connective Tissue Diseases (9) · Adenocarcinoma (1) · Carcinoma (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Neoplasms by Histologic Type (1) · Neoplasms, Ductal, Lobular, and Medullary (1) · Neoplasms, Glandular and Epithelial (1)
Letrozole (2) · Specimen Handling (2) · Anastrozole (1) · Ascorbic Acid (1) · Carmustine (1) · Early Intervention, Educational (1) · Fulvestrant (1) · Hydroxocobalamin (1) · Melphalan (1) · Motivational Interviewing (1) · Practice Guidelines as Topic (1) · Radiotherapy (1) · Standard of Care (1) · Vitamin B 12 (1) · abemaciclib (1)
Memorial Sloan Kettering Cancer Center (2) · Olema Pharmaceuticals, Inc. (2) · Alliance for Clinical Trials in Oncology (1) · General Oncology, Inc. (1) · Mayo Clinic (1) · Nancy Lin, MD (1) · University of California, San Francisco (1) · University of Washington (1)
United States (10) · Australia (2) · Austria (2) · Belgium (2) · Canada (2) · Czechia (2) · France (2) · Germany (2) · Hong Kong (2) · Hungary (2) · Italy (2) · Malaysia (2) · Netherlands (2) · Poland (2) · Portugal (2)
Arnold Glazier, M.D. (1) · Katherine E. Reeder-Hayes, MD (1) · Laura Huppert, MD,BA (1) · Lior Braunstein, MD (1) · Mary Disis (1) · Nancy Lin, MD (1) · Pooja Advani, MBBS, MD (1)
R01CA237357 (1), UG1CA189823 (1)